Exozymes (EXOZ) Return on Capital Employed (2024 - 2026)
Exozymes (EXOZ) posted quarterly Return on Capital Employed of 184.08% for Q4 2025, down 9890.0% year-over-year from 1.88% in Q4 2024, and down 52.5% quarter-over-quarter from 120.71% in Q3 2025.
Exozymes (EXOZ) Return on Capital Employed (2024 - 2026) Analysis & Trends
Exozymes (EXOZ) has reported Return on Capital Employed for 2 consecutive years, with 184.08% the latest figure, recorded in Q4 2025.
- In Q4 2025, Return on Capital Employed fell 9890.0% year-over-year to 184.08%; the TTM figure through Dec 2025 stood at 184.08% (down 9890.0% YoY), while the FY2025 annual figure was 122.43%, down 3724.0% from the prior year.
- Return on Capital Employed eased to 184.08% in Q4 2025 per EXOZ's latest filing, from 120.71% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 63.44% in Q1 2025 and bottomed at 184.08% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 7.88% |
| 10 | Exozymes | 64.09 Mn | 64.09 Mn | - | -200.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -200.03% |
| Dec 31, 2025 | -184.08% |
| Sep 30, 2025 | -120.71% |
| Jun 30, 2025 | -86.25% |
| Mar 31, 2025 | -63.44% |
| Dec 31, 2024 | -85.18% |